This article first appeared on GuruFocus .
-
GAAP Net Loss:$6.6 million for Q2 2026, compared to a $12.3 million loss in the prior year quarter.
-
GAAP Net Loss Attributable to PAVmed:$5.5 million, or $0.87 per share, for the second quarter.
-
Non-GAAP Net Loss:$1.7 million, or $0.27 per share, for the second quarter.
-
Non-GAAP Operating Expenses:$6.1 million in Q2 2026, up approximately $200,000 from the previous quarter.
-
R&D Expenses (Non-GAAP):Increased by approximately $650,000 sequentially and $1.3 million year-over-year, largely for the Veris implantable device.
-
Cash Position:$3.8 million at June 30, 2026.
-
Equity Method Investment Balance:$33 million, reflecting the mark-to-market of Lucid shares at $1.07 per share on June 30.
-
Shares Outstanding:Approximately 7.3 million shares including unvested RSAs; GAAP quarter-end shares were 6.3 million.
-
Fair Value Changes:Non-cash charge of approximately $3.1 million in Q2 2026, compared to $10.8 million in the prior year quarter.
Release Date: August 14, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Lucid's new positive EsoGuard coverage policy from Concert, with multiple client health plans adopting it, expands commercial coverage.
-
VARIS commercial phase at Ohio State University is accelerating, with patient onboarding increasing and a large purchase order secured.
-
PortIO's first-in-human results published in the Journal of Vascular Access, showing 100% device patency and no device-related adverse events.
-
Potential shift to a 510(k) regulatory pathway for PortIO could shorten timeline and reduce capital requirements for commercialization.
-
PAVmed's financial position improved with a $30 million Series D preferred stock offering and a $15 million senior secured note, reducing net loss year-over-year.
Negative Points
-
Cash at June 30 is only $3.8 million, which may not be sufficient to fund operations without additional financing.
-
The company's net loss, though reduced, remains significant at $5.5 million GAAP for the quarter.
-
R&D expenses increased by $1.3 million year-over-year, primarily for the VARIS implantable device, putting pressure on cash flow.
-
The equity method investment in Lucid decreased in value, with shares dropping from $1.09 to $1.07, reflecting market volatility.
-
The Octeris project is still several years away from commercialization, requiring ongoing investment without near-term revenue.
Q & A Highlights
Q: What is the anticipated regulatory pathway for PortIO, and could a 510(k) pathway be possible? A: Lishan Aklog, Chairman and CEO, stated that while prior FDA engagement suggested a De Novo pathway, consultations with regulatory experts and the publication of successful first-in-human data may allow for a straight 510(k) pathway. This would significantly shorten the timeline and reduce capital requirements. The company plans to submit a pre-submission meeting request in Q4 2026, with the actual meeting potentially occurring in early 2027.
Q: Can you provide more details on the commercial traction and patient onboarding for the Veris platform at Ohio State University? A: Lishan Aklog, Chairman and CEO, noted that while hard numbers aren't being disclosed, the strategic partnership with OSU's James Cancer Hospital involves a commitment to enroll 1,000 commercial patients in a registry within a year. With EHR integration complete and two-thirds of planned departments onboarded, patient onboarding is accelerating, and the 1,000-patient target is considered attainable.
Q: What will the upcoming clinical validation study for Octeris demonstrate, and what is the timeline to FDA submission? A: Lishan Aklog, Chairman and CEO, explained that the validation study will confirm the modified, smaller probe's performance and ergonomics, building on prior clinical work that established the technology's ability to measure nuclear size to detect esophageal dysplasia. The study is a step toward design freeze, and the overall project remains several years away from FDA submission, with console development potentially running in parallel.
Q: Does PAVmed hold global rights for PortIO and the Octeris technology? A: Lishan Aklog, Chairman and CEO, confirmed that PAVmed owns full rights to PortIO as it is internal IP, and the license with Duke University for Octeris includes worldwide rights.
Q: What is the commercialization plan for PortIO if the 510(k) pathway is successful? A: Lishan Aklog, Chairman and CEO, stated that a clear plan is in place, targeting vascular surgeons and interventional radiologists who currently implant vascular access devices. The company is working on pricing and coding and has flexibility to launch with a small sales team or partner with distributors active in the vascular access space.
Q: What is the current financial position and how has the company's capital structure changed? A: Dennis McGrath, CFO, reported cash of $3.8 million at June 30, 2026. The company completed a $30 million Series D preferred offering and issued a $15 million senior secured note to redeem all Series C preferred shares and retire existing convertible debt. The Series D shares were mandatorily converted to common stock, and $30 million in warrants are callable upon a positive EsoGuard LCD, with an additional $2.5 million from Veris warrants callable upon FDA clearance of the implantable device.
Q: What were the key financial results for the second quarter of 2026? A: Dennis McGrath, CFO, reported a GAAP net loss of $6.6 million, improved from a $12.3 million loss in the prior year quarter, driven by lower non-cash fair value charges. The GAAP net loss attributable to PAVmed was $5.5 million, or $0.87 per share, while the non-GAAP loss was $1.7 million, or $0.27 per share. Non-GAAP operating expenses were $6.1 million, with increases tied to Veris R&D.
Q: What is the status of the Lucid Diagnostics investment and its impact on PAVmed? A: Dennis McGrath, CFO, noted that PAVmed remains the largest common shareholder of Lucid with ~15% ownership and ~25% voting interest. The equity method investment balance is $33 million, reflecting Lucid's mark-to-market value. PAVmed continues to benefit from Lucid's progress, including new positive EsoGuard coverage policies and VA commercialization efforts.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
